Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05795842 · ClinicalTrials.gov registry record
DELTA (Detecting and Predicting Atrial Fibrillation in Post-Stroke Patients)
A clinical trial of Stroke, Ischemic, sponsored by Emory University.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT05795842 is a study of Stroke, Ischemic that is actively recruiting participants, run by Emory University. The registered enrollment target is 500 participants, above the 274-participant average among 33 other Stroke, Ischemic trials with a reported enrollment target (82% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05795842, a study of Stroke, Ischemic, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Atrial Fibrillation (AF) is an abnormal heart rhythm. Because AF is often asymptomatic, it often remains undiagnosed in the early stages. Anticoagulant therapy greatly reduces the risks of stroke in patients diagnosed with AF. However, diagnosis of AF requires long-term ambulatory monitoring procedures that are burdensome and/or expensive. Smart devices (such as Apple or Fitbit) use light sensors (called "photoplethysmography" or PPG) and motion sensors (called "accelerometers") to continuously record biometric data, including heart rhythm. Smart devices are already widely adopted. This study seeks to validate an investigational machine-learning software (also called "algorithms") for the long-term monitoring and detection of abnormal cardiac rhythms using biometric data collected from consumer smart devices. The research team aims to enroll 500 subjects who are being followed after a stroke event of uncertain cause at the Emory Stroke Center. Subjects will undergo standard long-term cardiac monitoring (ECG), using FDA-approved wearable devices fitted with skin electrodes or implantable continuous recorders, and backed by FDA-approved software for abnormal rhythm detection. Patients will wear a study-provided consumer wrist device at home, for the 30 days of ECG monitoring, 23 hours a day. At the end of the 30 days, the device data will be uploaded to a secure cloud server and will be analyzed offline using proprietary software (called "algorithms") and artificial intelligence strategies. Detection of AF events using the investigational algorithms will be compared to the results from the standard monitoring to assess their reliability. Attention will be paid to recorded motion artifacts that can affect the quality and reliability of recorded signals. The ultimate aim is to establish that smart devices can potentially be used for monitoring purposes when used with specialized algorithms. Smart devices could offer an affordable alternative to standard-of-care car
Conditions Studied
Interventions
- DEVICE wearable wristband model
- OTHER Samsung Galaxy Watch 6
- DEVICE Standard of care extended ECG monitoring
Study Locations (1)
Georgia
- Emory Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-03-21 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05795842
The ClinicalTrials.gov registry entry for NCT05795842 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 274-participant average among 33 other Stroke, Ischemic trials with a reported enrollment target (82% higher). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stroke, Ischemic appearing as the primary indexed condition, and to 3 interventions - of which wearable wristband model is the first listed.
NCT05795842 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05795842 about?
NCT05795842 is a clinical study titled "DELTA (Detecting and Predicting Atrial Fibrillation in Post-Stroke Patients)". Atrial Fibrillation (AF) is an abnormal heart rhythm. Because AF is often asymptomatic, it often remains undiagnosed in the early stages. Anticoagulant therapy greatly reduces the risks of stroke in patients diagnosed with AF. However, diagnosis of AF requires long-term ambulatory monitoring procedu...
What is the current status of trial NCT05795842?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-03-21. Estimated completion is 2028-12.
What conditions does trial NCT05795842 study?
This clinical trial studies the following conditions: Stroke, Ischemic.
What interventions are being tested in trial NCT05795842?
The interventions under investigation include: wearable wristband model (DEVICE), Samsung Galaxy Watch 6 (OTHER), Standard of care extended ECG monitoring (DEVICE).
Who is sponsoring clinical trial NCT05795842?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05795842 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke, Ischemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hand and Arm Motor Recovery Via Non-invasive Electrical Spinal Cord Stimulation After Stroke
RECRUITING · NA
-
The Fourth Left Atrial Appendage Occlusion Study
RECRUITING · NA
-
Study of Circulating Monocytes in Patients With Ischemic Vascular Disease
RECRUITING
-
Intra-Arterial Neuroprotective Agents and Cold Saline in Ischemic Stroke Intervention
RECRUITING · Phase 1
-
Promoting Recovery After STroke With Amantadine
RECRUITING · Phase 2
-
Vision Loss Impact on Navigation in Virtual Reality
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.